CMV-Based Vaccine Protects Against Ebola Virus
Author Information
Author(s): Tsuda Yoshimi, Caposio Patrizia, Parkins Christopher J., Botto Sara, Messaoudi Ilhem, Cicin-Sain Luka, Feldmann Heinz, Jarvis Michael A.
Primary Institution: National Institute of Allergy and Infectious Diseases, National Institutes of Health
Hypothesis
A vaccine strategy using CMV-based vectors expressing EBOV antigens may be ideally suited for use in inaccessible wildlife populations.
Conclusion
This study demonstrates the ability of a CMV-based vaccine approach to protect against a highly virulent human pathogen, and supports the potential for disseminating CMV-based EBOV vaccines to prevent EBOV transmission in wildlife populations.
Supporting Evidence
- MCMV/ZEBOV-NPCTL induced high levels of long-lasting CD8+ T cells against ZEBOV NP in mice.
- All vaccinated animals were protected against lethal ZEBOV challenge.
- Low levels of anti-ZEBOV antibodies were only sporadically detected in vaccinated animals prior to ZEBOV challenge.
Takeaway
Researchers created a vaccine using a virus that can spread easily among animals, which protected mice from a deadly virus called Ebola.
Methodology
Mice were vaccinated with a CMV-based vector expressing a CD8+ T cell epitope from the nucleoprotein of Zaire ebolavirus and then challenged with lethal doses of the virus.
Limitations
The study was conducted in a mouse model, which may not fully replicate the immune response in humans or other species.
Participant Demographics
C57BL/6 and 129S1/SvlmJ/Cr mice were used in the study.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website